Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial

Rama Bozorgmehr1, Farbod Amiri2, Mohammad Hosein Zadeh3

  • 1Clinical Research Development Unit, Shohada-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Insights

Sofosbuvir treatment may reduce hospitalization duration for moderate COVID-19 patients. This antiviral did not significantly impact intensive care unit (ICU) admission or mortality rates in the study.

Area of Science:

  • Infectious Diseases
  • Virology
  • Clinical Medicine

Background:

  • The COVID-19 pandemic necessitates ongoing research into effective treatments.
  • Moderate severity COVID-19 cases require interventions to manage hospital stay and prevent complications.

Purpose of the Study:

  • To evaluate the efficacy of sofosbuvir in reducing hospital stay for moderate COVID-19 patients.
  • To assess the impact of sofosbuvir on complications, including intensive care unit (ICU) admission and mortality.

Main Methods:

  • A randomized clinical trial involving 100 moderate COVID-19 patients.
  • Patients were allocated to either sofosbuvir intervention or control groups.
  • Outcomes measured included length of hospital stay and complication rates.

Main Results:

  • The sofosbuvir group had a significantly shorter mean hospital stay (4.7 days) compared to the control group (7.7 days).
  • No significant difference was observed in the need for ICU admission or mechanical ventilation between groups.
  • Patient demographics and baseline characteristics were comparable between the intervention and control groups.

Conclusions:

  • Sofosbuvir shows potential in decreasing the length of hospital stay for moderate COVID-19.
  • The study found no significant effect of sofosbuvir on ICU admission or mortality in this patient cohort.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.3K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Hospitals-II00:59

Hospitals-II

Hospitals provide inpatient and outpatient services. Inpatient services provide care to patients that stay in the hospital for an extended period, ranging from days to months. Examples of inpatient services include intensive care units, hospital wards, or surgeries. Outpatient services provide care to patients who come to a hospital for a diagnostic or treatment but do not stay overnight —for example, diagnostic tests, surgical procedures, or health education.
Nurses that work in...
823
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.7K